P3.07-009 Use of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: The Real-World Clinical Practice in Taiwan: Topic: Therapy and Economics

Abstract

Adjuvant chemotherapy is the standard treatment for selected patients with non-small cell lung cancer (NSCLC) following curative surgery. This study evaluated the use of adjuvant chemotherapy for these cases among the general population in Taiwan. A population-based cohort was established by searching the database of the Taiwan Cancer Registry System to identify patients newly diagnosed with NSCLC for the period covering 2005 to 2009. Our target was patients with stage I, II and IIIA NSCLC who had undergone curative surgery. Medication prescription data were retrieved from the National Health Insurance Research Database, Taiwan. Chemotherapy administered within 3 months after the surgery was defined as adjuvant chemotherapy. A total of 5789 patients received curative surgery for NSCLC, and the 1277 (22.1%) who had undergone adjuvant chemotherapy were included in this study. Overall, the most common adjuvant chemotherapy regimen was platinum plus gemcitabine (P + G) (25.7%), followed by platinum plus vinorelbine (P + V) (18.4%). For patients with stage II or IIIA disease, P + G remained the most common regimen, respectively (29.0% and 29.0%). However, for patients with stage I disease, the most common regimen was tegafur/uracil (30.7%). Analyzed by the diagnosis year, P + G was the most common adjuvant chemotherapy regimen until overtaken by P + V in 2009. Platinum plus gemcitabine regimen was the most commonly used adjuvant chemotherapy regimen in patients with operated stage II and IIIA NSCLC in Taiwan from 2005 to 2009.